Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 7,009 matching trials from the live ClinicalTrials.gov search.
Conditions
Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Deafness, Diabetes Insipidus, Ataxia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
0 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Metastatic Cancer, Renal Cancer
Interventions
Atezolizumab, Bevacizumab, Entinostat
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Educating Missouri Patients About Preemptive Living Donor Transplantation

NCT01048437
Conditions
Chronic Kidney Disease, End Stage Renal Disease
Interventions
Transplant education with video, Transplant education with speakers
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
Overland Park, Kansas • Springfield, Missouri • St Louis, Missouri + 1 more
Conditions
Urinary Bladder, Overactive
Interventions
Treament, Sham Control
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Woodbury, Minnesota • Seattle, Washington
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms
Interventions
ZD6126, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Los Angeles, California • Newark, Delaware • Tampa, Florida + 13 more
Completed Not applicable Interventional Accepts healthy volunteers

Hybrid Fractional Laser Treatment for Symptoms of Urinary Incontinence

NCT03180372
Conditions
Urinary Incontinence, Stress Urinary Incontinence, Urge Incontinence
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Gatos, California • Pensacola, Florida • Charlotte, North Carolina + 2 more
Conditions
Kidney Failure, Renal Dialysis
Interventions
Grafts placement
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
bevacizumab, temsirolimus
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Conditions
Urinary Tract Infection, Antibiotic, Catheter Infection
Interventions
0.05% Chlorhexidine Gluconate, Normal Saline
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
17
States / cities
Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
Terminated No phase listed Observational Accepts healthy volunteers

Radiation Therapy on Pelvic Floor Disorders in Women

NCT04623515
Conditions
Colorectal Cancer
Interventions
REDCap Questionnaires
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Metastatic Renal Cell Carcinoma, Skin Leiomyoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Uterine Corpus Leiomyoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mercaptopurine, Questionnaire Administration, Skin Biopsy
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Urinary Bladder, Overactive
Interventions
MagPro R30
Device
Lead sponsor
EMKinetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Conditions
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions
BT8009, Pembrolizumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more
Conditions
Cardiorenal Syndrome (CRS)
Interventions
Candesartan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Bladder Cancer
Interventions
Educational Videos
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Kidney Diseases, Chronic Kidney Diseases, End Stage Renal Disease, End Stage Renal Disease on Dialysis, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
IHI Breakthrough Collaborative Model
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Arvada, Colorado • Thornton, Colorado • Westminster, Colorado + 9 more
Conditions
Metastatic Renal Cell Carcinoma, Kidney Cancer
Interventions
Bevacizumab and Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
Interventions
Tazemetostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Hydroxychloroquine, IL-2
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
7
States / cities
Maywood, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 4 more
Conditions
Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
6 Years to 16 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
Conditions
Hemodialysis, Chronic Kidney Disease, Inflammation
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Sacramento, California
Completed Phase 2 Interventional Results available

A Research Study for Patients With Overactive Bladder

NCT00168454
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
botulinum toxin Type A, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania